{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:25Z","timestamp":1784119585389,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10792-019-01269-4","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T09:03:25Z","timestamp":1578647005000},"page":"1007-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics of \u2018sawtooth shunt\u2019 following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-3225","authenticated-orcid":false,"given":"Tapas Ranjan","family":"Padhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraprasad","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Sutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Khalsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"1269_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"An International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"An International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"key":"1269_CR2","first-page":"373","volume":"4","author":"X Katz","year":"2000","unstructured":"Katz X, Kychenthal A, Dorta P (2000) Zone I retinopathy of prematurity. JAAPOS 4:373\u2013376","journal-title":"JAAPOS"},{"issue":"4 Suppl","key":"1269_CR3","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser KA, Trese MT, Capone A Jr (2010) Aggressive posterior retinopathy of prematurity. Retina 30(4 Suppl):S37\u201340","journal-title":"Retina"},{"issue":"4","key":"1269_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/bjophthalmol-2011-300321","volume":"96","author":"G Sanghai","year":"2012","unstructured":"Sanghai G, Dogra MR, Dogra M et al (2012) A hybrid form of retinopathy of prematurity. Br J Ophthalmol 96(4):519\u2013522","journal-title":"Br J Ophthalmol"},{"key":"1269_CR5","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S et al (2015) Intravitreal bevacizumab monotherapy for type 1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity- 27\u00a0month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 253:1677\u20131683","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1269_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/eye.2015.240","volume":"30","author":"TR Padhi","year":"2016","unstructured":"Padhi TR, Das T, Rath S et al (2016) Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in Zone I. Eye 30(3):392\u2013399","journal-title":"Eye"},{"issue":"2","key":"1269_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10384-008-0622-y","volume":"53","author":"L Wu","year":"2009","unstructured":"Wu L, Arevalo JF, Maia M et al (2009) Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 53(2):125\u2013130","journal-title":"Jpn J Ophthalmol"},{"issue":"14","key":"1269_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) ANCHOR study group ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432\u20131444","journal-title":"N Engl J Med"},{"key":"1269_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","volume":"34","author":"RL Avery","year":"2014","unstructured":"Avery RL, Bakri SJ, Blumenkranz et al (2014) Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina 34:S1\u2013S18","journal-title":"Retina"},{"key":"1269_CR10","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1097\/IAE.0000000000001561","volume":"37","author":"LM Wright","year":"2017","unstructured":"Wright LM, Vrcek IM, Scribbick FW et al (2017) Technique for infant intravitreal injection in treatment of retinopathy of prematurity. Retina 37:2188\u20132190","journal-title":"Retina"},{"issue":"6","key":"1269_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, Son AK et al (2017) Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a Phase 1 Dosing Study. JAMA Ophthalmol 135(6):654\u2013656","journal-title":"JAMA Ophthalmol"},{"key":"1269_CR12","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1167\/iovs.10-7108","volume":"52","author":"Q Fan","year":"2011","unstructured":"Fan Q, TeoYY Saw SM (2011) Application of advanced statistics in ophthalmology. Inves Ophthalmol Vis Sci 52:6059\u20136065","journal-title":"Inves Ophthalmol Vis Sci"},{"key":"1269_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0161-6420(79)35329-5","volume":"86","author":"JT Flynn","year":"1979","unstructured":"Flynn JT, Cassady J, Essner D et al (1979) Fluorescein angiography in retrolental fibroplasia: experience from 1969\u20131977. Ophthalmology 86:1700\u20131723","journal-title":"Ophthalmology"},{"key":"1269_CR14","first-page":"54","volume":"80","author":"H Morizane","year":"1976","unstructured":"Morizane H (1976) Initial sign and clinical course of the most severe form of acute proliferative retrolental fibroplasias (type II) [in Japanese]. Nippon GankaGakkaiZasshi 80:54\u201361","journal-title":"Nippon GankaGakkaiZasshi"},{"key":"1269_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ophtha.2009.01.038","volume":"116","author":"T Yokoi","year":"2009","unstructured":"Yokoi T, Hiraoka M, Miyamoto M et al (2009) Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology 116:1377\u20131382","journal-title":"Ophthalmology"},{"key":"1269_CR16","first-page":"1","volume":"39","author":"CA Harper III","year":"2017","unstructured":"Harper CA III, Wright LM, Young RC et al (2017) Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity. Retina 39:1\u20136","journal-title":"Retina"},{"key":"1269_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/aos.12461","volume":"92","author":"SW Park","year":"2014","unstructured":"Park SW, Jung HH, Heo H (2014) Fluorescein angiography of aggressive retinopathy of Prematurity treated with intravitreal anti-VEGF in large preterm babies. Acta Ophthalmol 92:810\u2013813","journal-title":"Acta Ophthalmol"},{"key":"1269_CR18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212\u20132219","journal-title":"Ophthalmology"},{"key":"1269_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M et al (2017) on behalf of the Giessen Cooperative ROP study group. Retinal vascular development with 0.312\u00a0mg intravitreal bevacizumab to treat severe posterior Retinopathy of Prematurity a longitudinal fluorescein angiographic study. Retina 37:97\u2013111","journal-title":"Retina"},{"key":"1269_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC et al (2014) Fluorescein angiographic observations of peripheral retinal vessel outgrowth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507\u2013512","journal-title":"Br J Ophthalmol"},{"key":"1269_CR21","first-page":"120","volume":"18","author":"A Henaine-Berra","year":"2014","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H et al (2014) Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. JAAPOS 18:120\u2013123","journal-title":"JAAPOS"},{"issue":"6","key":"1269_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00417-019-04292-4","volume":"257","author":"I Perente","year":"2019","unstructured":"Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257(6):1141\u20131146. https:\/\/doi.org\/10.1007\/s00417-019-04292-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1269_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-019-01088-7","author":"DY Ekinci","year":"2019","unstructured":"Ekinci DY, Vural AD, Bayramoglu SE, Onur IU, Hergunsel GO (2019) Assessment of vascular leakage and its development with FFA among patients treated with intravitreal Anti-VEGF due to aggressive posterior ROP. Int Ophthalmol. https:\/\/doi.org\/10.1007\/s10792-019-01088-7","journal-title":"Int Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-019-01269-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:06:25Z","timestamp":1610150785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-019-01269-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1007\/s10792-019-01269-4","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}